Introduction/Background Treatment of locally advanced cervical carcinoma regardless of histology, either, squamous, adeno- or adenosquamous carcinoma is the same, concurrent chemoradiotherapy. Nevertheless, studies have different and contradictory results regarding the impact of tumor histology in relation to treatment response. The current study sought to determine the clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma of the cervix in comparison to squamous cell carcinoma.
Methodology Records of the cervical cancer patients from the outpatient department of the Section of Gynecologic Oncology of a tertiary hospital were retrospectively reviewed.
Results Among the 979 charts reviewed, only 278 patients were included in the analysis. Seventy-five percent of the patients had squamous cell carcinoma and only 20% had adenocarcinoma. Baseline characteristics were comparable. Ninety-eight percent had Cisplatin-based concurrent chemoradiotherapy. Median follow up was 17 months, with 75.30% of the patients had complete response, 7.97 had partial response and 16.73% had recurrent disease. Patients having squamous cell carcinoma had higher percentage of being alive at the time of follow up, better response to treatment, lesser recurrence and lower mortality rate as compared to adenocarcinoma, however, there was no sufficient evidence to demonstrate a difference in disease free survival and overall survival.
Conclusion Patients with locally advanced adenocarcinoma of the cervix who underwent concurrent chemoradiation had the same treatment response and prognosis to patients with squamous cell carcinoma.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.